InflaRx Halts Vilobelimab Development For Painful Skin Ulcers After Trial Fails To Show Efficacy

InflaRx N.V. (IFRX) is discontinuing the development of Vilobelimab for pyoderma gangrenosum after an interim analysis of its phase III trial indicated a lack of efficacy, as recommended by the Independent Data Monitoring Committee. The company will now focus on INF904 for immuno-dermatology indications, with initial phase IIa data expected this summer; Vilobelimab remains approved in Europe for SARS-CoV-2-induced acute respiratory distress syndrome under the brand name GOHIBIC.

Analysis

InflaRx N.V. has announced a significant setback with the decision to halt the development of Vilobelimab for pyoderma gangrenosum, a rare dermatological condition with no approved treatments in the U.S. or Europe. This decision followed a recommendation from the Independent Data Monitoring Committee (IDMC) after an interim analysis of the Phase III clinical trial data indicated a lack of efficacy. While Vilobelimab, marketed as GOHIBIC, retains its European Commission marketing authorization under exceptional circumstances for treating SARS-CoV-2-induced acute respiratory distress syndrome, the failure in pyoderma gangrenosum removes a key potential indication from its pipeline. Consequently, InflaRx will redirect its resources to prioritize INF904, an asset being developed for immuno-dermatology indications, specifically chronic spontaneous urticaria and hidradenitis suppurativa, within a single Phase IIa basket study. Initial data from this Phase IIa study are anticipated this summer and will be a critical determinant for the company's future. The company's stock (IFRX), which closed at $1.82 yesterday after a 1.62% decline and has traded in a range of $0.82 to $2.81 over the past year, is likely to face further scrutiny following this news, reflected by the moderately negative sentiment score (-0.6) associated with this development.

Key Decisions for Investors

• Investors should anticipate increased downside pressure on IFRX's stock price in the near term due to the discontinuation of the Vilobelimab Phase III trial for pyoderma gangrenosum.
• The forthcoming initial Phase IIa data for INF904, expected this summer, now represents a pivotal make-or-break catalyst for InflaRx and should be monitored closely.
• Re-evaluate portfolio exposure to IFRX, acknowledging the significantly altered risk profile and heightened dependency on the success of the earlier-stage INF904 program.
• While GOHIBIC's commercial performance in Europe for COVID-19 ARDS provides some revenue potential, its contribution is likely limited, and primary attention should be on the clinical progression of INF904.